Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Anavex Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Anavex Life Sciences's R&D Expenses for the twelve months ending Mar 31, 2026 was $26.10M, down 40.4% year over year. For fiscal 2025 it was $37.59M, down 10.1% from the year before. Over ten years it grew 32.4% a year on average. The highest annual figure on record is $43.72M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.59M | -10.1% |
| FY2024 | Sep 30, 2024 | $41.84M | -4.3% |
| FY2023 | Sep 30, 2023 | $43.72M | +15.3% |
| FY2022 | Sep 30, 2022 | $37.92M | +15.0% |
| FY2021 | Sep 30, 2021 | $32.98M | +30.7% |
| FY2020 | Sep 30, 2020 | $25.23M | +13.3% |
| FY2019 | Sep 30, 2019 | $22.26M | +66.8% |
| FY2018 | Sep 30, 2018 | $13.34M | +25.0% |
| FY2017 | Sep 30, 2017 | $10.67M | +47.1% |
| FY2016 | Sep 30, 2016 | $7.25M | +219.3% |
| FY2015 | Sep 30, 2015 | $2.27M | +210.2% |
| FY2014 | Sep 30, 2014 | $732.40K | +177.6% |
| FY2013 | Sep 30, 2013 | $263.85K | -90.1% |
| FY2012 | Sep 30, 2012 | $2.65M | +2.2% |
| FY2011 | Sep 30, 2011 | $2.60M | -4.8% |
| FY2010 | Sep 30, 2010 | $2.73M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $4.19M | -57.6% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $4.66M | -55.4% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $7.29M | -37.2% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $9.96M | -15.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $9.89M | +1.7% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $10.45M | +20.3% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $11.61M | +15.4% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $11.81M | +14.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $9.73M | -14.0% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $8.68M | -28.0% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $10.06M | -11.6% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $10.28M | +10.9% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $11.31M | +31.4% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $12.07M | +39.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $11.38M | +21.4% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $9.27M | +3.4% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $8.60M | +28.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $8.66M | +9.2% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $9.37M | +53.5% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $8.96M | +33.3% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $6.72M | +11.0% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $7.93M | +24.8% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $6.10M | +29.6% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $6.73M | +16.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $6.05M | -0.4% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $6.35M | +11.1% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $4.71M | +6.9% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $5.76M | +92.1% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $6.08M | +87.3% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $5.71M | +112.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $4.41M | +14.9% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $3.00M | +30.3% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $3.25M | +30.2% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $2.69M | +31.9% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $3.84M | +14.0% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $2.30M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $2.49M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $2.04M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $3.37M | – |
See a number that looks wrong?